Medical News

RSS

Medicago receives $3.8M as second milestone payment from U.S. DARPA for cGMP vaccine facility

Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the second milestone payment of US$3.8 million from the Defense Advanced Research Projects Agency ("DARPA").

15 Mar 2011

Raymond Associates, BioNeutral enter global sales and distribution agreement for Ygiene antimicrobial technology

BioNeutral Group, Inc., a specialty life science technology-based company, today announced that it has entered into a global sales and distribution agreement with Raymond Associates LLC, a Service Connected Certified Disabled Veteran-Owned Business and executive management consulting firm.

15 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

Newer, more expensive treatments for prostate cancer adopted rapidly

With 180,000 men diagnosed with prostate cancer each year, it is one of the most common types of cancer in the country. For this reason, it has been cited as a good marker for health care spending in general, reflective of the greater trends across the United States.

15 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Research links frequent prescribing to opioid-related deaths

Some physicians are prescribing opioids such as OxyContin 55 times as often as others, according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES). The study found most opioid-related deaths occur among patients treated by physicians who frequently prescribe opioids, suggesting doctors who prescribe a lot of opioids may not be doing so safely.

15 Mar 2011

Trend rising for deaths of children in cars and trucks

Sadly, March 8th marked the first child vehicular tragedy of the year when a mother came out of work only to realize she left her 6 month year old in the car. This preventable, yet horrific accident occurs more often than one would think.

15 Mar 2011

First Edition: March 15, 2011

Today's headlines include reports about the pace of legal challenges to the health law as well as ongoing congressional attempts to reach partisan agreement on a short-term budget bill to avert a government shutdown.

15 Mar 2011

XTIO2 presents XTI 360 ANTI-GERM SYSTEM to 83rd Academy Award-nominees

XTIO2 INC. (XTI) presented the 83rd Academy® Award-nominees with the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM, consisting of XTI 360™ Nanocoating and XTI™ Nano-Facemask. It is the world's most effective preventive measure and the best defense against germs transmitted via air and contact surfaces.

15 Mar 2011

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

DJO Global, Inc., a leading provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that one of its indirect subsidiaries has signed a definitive agreement to purchase Rikco International, LLC, D/B/A Dr. Comfort, for approximately $254.6 million in cash.

15 Mar 2011

Additional research needed for oral PrEP to treat HIV

The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert, Inc.

15 Mar 2011

AYA cancer patients require targeted care, say experts

Adolescents and young adults are neither children nor adults and those affected by cancer require targeted care that crosses the boundaries between pediatric and adult oncology, according to several pioneers in this still-developing field of adolescent and young adult oncology.

15 Mar 2011

Researchers receive NIH grant to study effects of BBTW treatment in patients with MS

Motion Therapeutics, Inc., the leading provider of noninvasive therapeutic solutions for balance and mobility disorders, today announced that researchers at Samuel Merritt University and San Francisco State received a NIH Recovery Act Grant to study the effects of wearing a strategically weighted vest to improve gait and mobility in people with MS.

15 Mar 2011

BioDrain retains CFSG1 as its U.S. Investor Relations representative

BioDrain Medical, Inc., producer of the FDA cleared Streamway System for automated surgical fluid disposal, announced today that it has retained Consulting for Strategic Growth 1 as its U.S. Investor Relations representative.

15 Mar 2011

Ingenuity announces new features to support RNA-Seq workflows, microRNA research in IPA

Ingenuity Systems, a leading provider of information and analytics solutions for life science researchers, today announced new features to support RNA-Sequencing workflows and microRNA research in IPA.

15 Mar 2011

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

15 Mar 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011